Emma Palmer Foster

The Chartered Institute of Public Relations is a professional organization committed to professional standards and lifelong learning for public relations professionals. The organization is based in London, UK and is the world's only royal chartered body for public relations professionals. The British company offers professional development opportunities, networking events, and support for their members. The CEO of the non-profit company is Alastair McCapra.

Discovery Park Ventures LLC (Discovery Park Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Seattle, Washington.

College Hill Life Sciences Ltd. provides public relation services. Its focus areas include financial public relations and investor relations, with specialist industry sector teams, corporate public relations, public affairs, branding, financial reporting and digital, risk and crisis management, employee engagement and strategic research consultancy. The company was founded by Sue Charles, Peter Colley and Katja Stout in 2002 and is headquartered in London, the United Kingdom.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality.